OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850
UNITED STATES
Phone: +1-888-267-4436
Fax: +1-301-340-8606
techsupport@origene.com

OriGene Technologies GmbH
Schillerstr. 5
32052 Herford
GERMANY
Phone: +49-5221-34606-0
Fax: +49-5221-34606-11
info-de@origene.com

AM32061PU-N Monoclonal Antibody to Ovarian Carcinoma-associated antigen - Purified

Quantity: 1 ml

Host / Isotype: Mouse / IgG2b

Recommended Isotype Controls: SM12P, AM03110PU-N

Clone: OV632

Format:
State: Liquid purified IgG fraction
Purification: Protein A Chromatography
Buffer System: PBS
Preservatives: 0.09% Sodium Azide
Stabilizers: 1% BSA

Applications:
Immunohistochemistry on Frozen Sections: Use at 1/10 preferably in PBS.
This antibody can only be used on frozen sections and is characterized using the indirect immunoperoxidase method. Cross reactions were investigated using the indirect immunoperoxidase method in a dilution of 1/10, which method is therefore recommended.
Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Specificity:
This antibody clone *OV632* stains 80% of non-mucinous primary and metastatic ovarian cancers. This monoclonal antibody is used for the identification of primary and metastatic nonmucinous ovarian carcinoma and ovarian carcinoma cells in peritoneal fluids. It rarely stains nongynecological malignancies using standard immunohistochemical conditions.

Cross reactivities:
breast carcinomas: not detectable
colon carcinomas: not detectable
other nongynecological malignancies: incidentally present
other gynecological adenocarcinomas: present
mesothelial cells: not detectable
mesotheliom: present

Species Reactivity: **Tested:** Human.

Storage:
Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

General Readings:
1. Immunocytochem. of malignant mesothelioma:, 1991, Journal of Pathology vol. 165, 137-143.
2. Boerman OC, van Niekerk CC, Makkink K, Hanselaar TG, Kenemans P, Poels LG. Comparative immunohistochemical study of four monoclonal antibodies directed

against ovarian carcinoma-associated antigens. Int J Gynecol Pathol. 1991;10(1):15-25. PubMed PMID: 2007534.
3. Delahaye M, Hoogsteden HC, Van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol. 1991 Oct;165(2):137-43. PubMed PMID: 1744800.
4. Boerman O, Massuger L, Makkink K, Thomas C, Kenemans P, Poels L. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res. 1990 Sep-Oct;10(5A):1289-95. PubMed PMID: 2241105.